BridgeBio Pharma, Inc. Research and Development in Process
BridgeBio Pharma, Inc. (BBIO) reported Research and Development in Process of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-23
- BridgeBio Pharma, Inc. research and development in process for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. research and development in process for the quarter ending 2019-09-30 was $1.06M.
- BridgeBio Pharma, Inc. research and development in process for the quarter ending 2019-06-30 was $500.00K.
- BridgeBio Pharma, Inc. research and development in process for the quarter ending 2019-03-31 was $2.00M.
- BridgeBio Pharma, Inc. research and development in process for fiscal 2022 was $0.00.
- BridgeBio Pharma, Inc. research and development in process for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BridgeBio Pharma, Inc. research and development in process for fiscal 2020 was $4.73M, a 32.78% increase from fiscal 2019.
- BridgeBio Pharma, Inc. research and development in process for fiscal 2019 was $3.56M, a 80.14% decline from fiscal 2018.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2020-12-31 | $4.73M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.06M derived: sum of 2 quarters · filed 2022-02-25 | $1.56M derived: sum of 3 quarters · filed 2022-02-25 | $3.56M 10-K · filed 2022-02-25 |
| 2019-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.56M derived: sum of 2 quarters · filed 2020-11-05 | $3.56M 10-Q · filed 2020-11-05 | $3.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $2.50M 10-Q · filed 2020-08-11 | $2.54M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.00M 10-Q · filed 2020-05-14 | $2.04M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $17.92M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $17.89M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |